Serum TIMP-1 in gastric cancer patients: A potential prognostic biomarker

Annals of Clinical and Laboratory Science

Volumn 36, Issue 1, 2006, Pages 23-30

  Wang, Chia Siu ^a   Wu, Tsu Lan ^a   Tsao, Kuo Chien ^a   Sun, Chien Feng ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Gastric cancer; TIMP 1; Tissue inhibitor of matrix metalloproteinase 1

Indexed keywords

BIOLOGICAL MARKER; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRECTOMY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PERITONEAL CAVITY; PROGNOSIS; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 33744471435     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Denhardt TD, Feng BO, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinase (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-341.
2. Brew K. Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
3. Stetler-Stevenson WG. Matrix metalloproteinases in angiogesis: a moving target for therapeutic intervension. J Clin Invest 1999;103:1237-1241.
4. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000;36:1621-1630.
5. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgis N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84:44-48.
6. Matsumoto E, Nakatsukasa H, Nouso K, Kobayashi Y, Nakamura S, Suzuki M, Takuma Y, Tanaka H, Fujikawa T, Shiratori Y. Increased levels of tissue inhibitor of metalloproteinase-1 in human hepatocellular carcinoma. Liver Int 2004;24:379-383.
7. Hoken-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brunner N, Fernebro E; EORTC-Receptor and Biomarker Group. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival, a validation study. Eur J Cancer 2004;40:64-72.
8. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y. Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma: a new biomarker for invasion and its impact on survival. Cancer 2001;91:1739-1744.
9. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996;69:9-16.
10. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H, Akiyoshi T. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76:531-536.
11. Hong SI, Park IC, Hong WS, Son YS, Lee SH, Lee JI, Choi DW, Moon NM, Choe TB, Jang JJ. Overexpression of tissue inhibitors of metalloproteinase-1 and -2 in the stroma of gastric cancer. J Korean Med Sci 1996;11:474-479.
12. Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K, et al. Prognostic impact of tissue inhibitor of martrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 2000;88:575-578.
13. Gress TM, Muller PF, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-sku localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995;62:407-413.
14. Fong K. M., Kida Y., Zimmerman P. V., Smith P. J. TIMP-1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996;2:1369-1372.
15. Kossakowska AE, Urbanski SJ, Edward DR. Tissue inhibitor of metalloproteinases-1 (TIMP-1)RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood 1991:77:2475-2482.
16. Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 2000;45:114-121.
17. Kallakury BV, Karikenhalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-3119.
18. Gong YL, Xu GM, Huang WD, Chen LB. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol 2000;73:95-99.
19. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Cancer Res 1997;3:1623-1628.
20. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Sevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastasis. Clin Cancer Res 1995;1:907-912.
21. Murray GI, Duncan ME, Aurbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-797.
22. Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 2003;9:899-904.
23. Yoshikawa T, Saitoh M, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, et al. Tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer - a possible marker for serosal invasion and metastasis. Cancer 1999;86:1929-1935.
24. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994;70:506-512.
25. Naruo S, Kanayama H, Takigawa H, Kagawa S, Yamashita K, Hayakawa T. Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int J Urol 1994;1:228-231.
26. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinasesl and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003;39: 1948-1956.
27. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20:1085-1091.
28. Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001;7:1633-1637.
29. Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, Imada T, Noguchi Y. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Anticancer Res 2004;24:2101-2106
30. Muzzillo DA, Imoto M, Fukuda Y, Koyama Y, Saga S, Nagai Y, Hayakawa T. Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. Gastroenterol Hepatol 1993;8:437-441.
31. Matusi Hkubochi K, Sshimada A, Hasumi A. Desmoplastic response in scirrhous gastric carcinoma: imbalance between collagen synthesis and degradation. Anticancer Res 2000;20:4733-4738.
32. Japanese Gastric Cancer Assoication. Japanese classification of gastric carcinoma. Gastric Cancer 1998;1:10-24.
33. Sobin LH, Wittekand CH (Eds). TNM Classification of Malignant Tumors, 6th ed, Wiley-Liss, New York, 2002.
34. Wu JT. Clinical applications. In: Human Circulating Tumor Markers: Current Concepts and Clinical Applications (Wu JT, Nakamura RM, Eds), Am Soc Clin Pathol, Chicago, 1997; pp 21-24.
35. Wang CS, Hsieh CC, Chao TC, Jan YY, Jeng LB, Huang TL, Chen MF, Chen PC, Chen JS, Hsueh S. Resectable gastric cancer: operative mortality and survival analysis. Chang Gung Med J 2002;25:216-226.
36. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005;8:86-94.
37. Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997;74:220-223.
38. Benassi MS, Magagnoli G, Ponticelli F, Pazzaglia L, Zanella L, Gamberi G, Ragazzini P, Ferrari C, Mercuri M, Picci P. Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas. Histol Histopathol 2003;18:1035-1040.
39. Giannelli G, Erriquez R, Fransvea E, Daniele A, Trerotoli P, Schittulli F, Grano M, Quaranta M, Antonaci S. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004;109:782-785.
40. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 2005;89:29-34.
41. Cooper TW, Eisen AZ, Stricklin GP, Welgus HG. Platelet-derived collagenase inhibitor: characterization and subcellular localization. PNAS USA 1985;82:2279-2283.
42. Holten-Andersen MN, Schrohl AS, Brunner N, Nielsen HJ, Hogdall CK, Hogdall EV. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 2003;18:170-176.
43. Koyama S. Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig Dis Sci 2004;49:1621-1630.
44. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sorensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brunner N. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002;8:156-164.
45. Wu JT. Tumor marker assay. In: Human Circulating Tumor Markers: Current Concepts and Clinical Applications (Wu JT, Nakamura RM, Eds), Am Soc Clin Pathol, Chicago, 1997; pp 161-178.
46. Hidlago M, Echhardt SG. Development of martrix metalloproteinase inhibitors in cancer therapy (review). J Natl Cancer Inst 2001;93:178-193.
47. Rhee JS, Diaz R, Korets L, Hodgson G, Coussens LM. TIMP-I alters susceptibility to carcinogenesis. Cancer Res 2004;64:952-961.
48. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002;86:1864-1870.